The FDA has approved aprepitant (Emend, Merck), in combination with other antiemetics, for the prevention of nausea and vomiting in patients undergoing moderately emetogenic chemotherapy, according to ...

A common anti-nausea drug used during chemotherapy may do more than ease discomfort, it could help women with aggressive breast cancers live longer, cutting the risk of death by up to 39% in some ...

APONVIE, an aprepitant product, highlighted as the only FDA-approved IV formulation Neurokinin-1 (“NK-1”) antagonist indicated for the prevention of PONV in adults, with a long half-life and quicker ...

Diagnostic Performance of Nanoparticle-Enhanced Magnetic Resonance Imaging in the Diagnosis of Lymph Node Metastases in Patients With Endometrial and Cervical Cancer This is the first study in which ...

Aprepitant is associated with improved survival outcomes in early-stage breast cancer, particularly in triple-negative cases, showing significant DDFS and BCSS improvements. The study analyzed 13,811 ...

Addition of aprepitant, an NK-1 receptor antagonist, to dexamethasone and a 5-HT3 receptor antagonist contributes substantially to emetic control in patients receiving 5-day cisplatin-containing ...

Bone marrow transplant patients say two of the most debilitating side effects of the treatment are nausea and vomiting caused by chemotherapy and radiation. Bone marrow transplant patients say two of ...

Review the side-effects of Aprepitant as documented in medical literature. The term "side effects" refers to unintended effects that can occur as a result of taking the medication. In majority of the ...

Rates of postoperative nausea and vomiting were greatly reduced in patients who took preoperative aprepitant with ondansetron within 1 hour before facial plastic surgery compared with ondansetron ...

In this retrospective study, we present data on a consecutive case series of 85 patients (aprepitant group: n=14, control group: n=71) treated with a tacrolimus/sirolimus-based GVHD prophylactic ...

Randomized Phase III Trial of Retinoic Acid and Arsenic Trioxide Versus Retinoic Acid and Chemotherapy in Patients With Acute Promyelocytic Leukemia: Health-Related Quality-of-Life Outcomes This ...

LAS VEGAS -- The primary endpoint was missed in the so-called APRON trial of aprepitant (Emend), a neurokinin-1 receptor antagonist, for symptoms of gastroparesis but the drug shouldn't be completely ...